Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mitchell Cagle

Nurse Practitioner, Family Northport, AL Nurse Practitioner

NPI 1306396676 CMS profile 11047730

952 Rose Dr, Northport, AL 35476

Open in the dashboard

General payments

$13,372

757 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mitchell Cagle of Northport, AL is reported in the CMS Open Payments database as having received $13,372 across 757 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,860 107
2024 General $2,106 123
2023 General $2,981 156
2022 General $3,029 178
2021 General $3,396 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Cagle
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Mitchell Cagle were reported at $1,860. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Mitchell Cagle Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,396 $124 $35–$379 $132
2022 $3,029 $141 $44–$430 $149
2023 $2,981 $154 $49–$476 $160
2024 $2,106 $165 $51–$504 $164
2025 $1,860 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,722 105 payments
  2. Novo Nordisk Inc $1,202 71 payments
  3. AstraZeneca Pharmaceuticals LP $982 51 payments
  4. Pfizer Inc. $911 58 payments
  5. Lilly USA, LLC $900 51 payments
  6. GlaxoSmithKline, LLC. $877 69 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $721 33 payments
  8. Daiichi Sankyo Inc. $713 34 payments
  9. Novartis Pharmaceuticals Corporation $584 41 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $503 25 payments
  11. Other $4,257 219 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,272 756 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,043 54 payments
  2. TRELEGY ELLIPTA $877 69 payments
  3. Ozempic $847 59 payments
  4. RYBELSUS $810 59 payments
  5. MOUNJARO $720 40 payments
  6. INJECTAFER $713 34 payments
  7. FARXIGA $712 40 payments
  8. ELIQUIS $602 33 payments
  9. Kerendia $503 25 payments
  10. XARELTO $495 27 payments
  11. Other $8,623 498 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

757 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record